Orchid Pharma delivered a strong turnaround in the June 2026 quarter, reporting a consolidated net profit of ₹3.22 crore compared to a net loss of ₹5.69 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a significant improvement in the company's financial performance during the first quarter of FY27.
The pharmaceutical company demonstrated robust revenue growth with sales rising 15.57% to ₹304.17 crore in Q1 FY27, as reported by Business Standard. This compares to sales of ₹263.19 crore recorded in the same quarter of the previous financial year, indicating strong operational performance across the company's business segments.
The company's operating profit margin (OPM) improved significantly to 4.60% in the June 2026 quarter from 2.14% in the corresponding quarter of the previous year, as reported by Business Standard. This substantial improvement in operational efficiency contributed to the overall profitability turnaround and enhanced the company's bottom-line performance during the quarter.
Profit before tax (PBT) turned positive at ₹2.65 crore in the June 2026 quarter compared to a loss of ₹6.89 crore in the previous year's corresponding quarter, according to Business Standard reports. Additionally, PBDT (Profit Before Depreciation and Tax) increased substantially by 274% to ₹13.60 crore from ₹3.64 crore in the same quarter last year, reflecting improved operational performance across the company's business segments.
